FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2275764539> ?p ?o ?g. }

• W2275764539 abstract "OBJECTIVE: This post-hoc subanalysis of the Phase III CONTAIN trial evaluated the incidence and time to resolution of somnolence and sedation for patients with LGS. BACKGROUND: Somnolence and sedation are common adverse events related to treatment with benzodiazepines. It has been hypothesized that treatment with clobazam may be less frequently associated with these types of AEs than treatment with 1,4-benzodiazepines. DESIGN/METHODS: The CONTAIN trial compared 3 oral dosages of clobazam with placebo as adjunctive therapy for LGS. Patients 2–60 years of age with LGS enrolled. Following a 4-week baseline phase, patients who had ≥2 drop seizures per week were randomized to placebo or 1 of 3 dosages of clobazam (0.25, 0.5, and 1.0 mg/kg/day), up to a maximum daily dosage of 40 mg. Treatment included a 3-week titration phase, followed by a 12-week maintenance phase. The safety population included all who received ≥1 dose of study drug or placebo. Incidence, time to onset, duration, and time to resolution of somnolence-related AEs (defined as somnolence and sedation) were analyzed for patients treated with placebo, or low-, medium-, or high-dosage clobazam. RESULTS: The incidence of somnolence and/or sedation was greater for patients treated with clobazam (26%) than patients treated with placebo (15%). Further, the incidence increased with greater dosages of clobazam (low-dosage, 17%; medium-dosage, 27%; and high-dosage, 32%). For most patients, onset of these events was within the first 3 weeks of treatment (during titration). The majority of these events resolved (placebo, 73%; low-dosage, 82%; medium-dosage, 63%; and high-dosage, 83%). The median duration of these somnolence-related adverse events was within 2–3 weeks for all clobazam treatment groups. CONCLUSIONS: Somnolence and sedation were relatively common AEs observed during clobazam treatment in CONTAIN, and were dosage-related. However, most of these events were transient and resolved within a few weeks. Supported by: Lundbeck LLC. Disclosure: Dr. Renfroe has received research support from Lundbeck Research USA. Dr. Isojarvi has received personal compensation for activities with Lundbeck as an employee. Dr. Lee has received personal compensation for activities with the Foundation for Peripheral Neuropathy as an advisory board member.Dr. Lee has received personal compensation for activities with Lundbeck as an employee. Dr. Lee hold stock and stock options in Baxter." @default.
• W2275764539 created "2016-06-24" @default.
• W2275764539 creator A5027959811 @default.
• W2275764539 creator A5060176494 @default.
• W2275764539 creator A5073284312 @default.
• W2275764539 date "2013-02-12" @default.
• W2275764539 modified "2023-09-26" @default.
• W2275764539 title "Somnolence and Sedation Were Transient Adverse Events for Most Patients Receiving Clobazam Therapy during the CONTAIN Study in Lennox-Gastaut Syndrome (LGS) (P04.208)" @default.
• W2275764539 hasPublicationYear "2013" @default.
• W2275764539 type Work @default.
• W2275764539 sameAs 2275764539 @default.
• W2275764539 citedByCount "0" @default.
• W2275764539 crossrefType "journal-article" @default.
• W2275764539 hasAuthorship W2275764539A5027959811 @default.
• W2275764539 hasAuthorship W2275764539A5060176494 @default.
• W2275764539 hasAuthorship W2275764539A5073284312 @default.
• W2275764539 hasConcept C118552586 @default.
• W2275764539 hasConcept C126322002 @default.
• W2275764539 hasConcept C142724271 @default.
• W2275764539 hasConcept C162156334 @default.
• W2275764539 hasConcept C197934379 @default.
• W2275764539 hasConcept C204787440 @default.
• W2275764539 hasConcept C27081682 @default.
• W2275764539 hasConcept C2776814716 @default.
• W2275764539 hasConcept C2777907850 @default.
• W2275764539 hasConcept C2778186239 @default.
• W2275764539 hasConcept C2778375690 @default.
• W2275764539 hasConcept C2779034229 @default.
• W2275764539 hasConcept C2779307984 @default.
• W2275764539 hasConcept C2908647359 @default.
• W2275764539 hasConcept C42219234 @default.
• W2275764539 hasConcept C71924100 @default.
• W2275764539 hasConcept C99454951 @default.
• W2275764539 hasConceptScore W2275764539C118552586 @default.
• W2275764539 hasConceptScore W2275764539C126322002 @default.
• W2275764539 hasConceptScore W2275764539C142724271 @default.
• W2275764539 hasConceptScore W2275764539C162156334 @default.
• W2275764539 hasConceptScore W2275764539C197934379 @default.
• W2275764539 hasConceptScore W2275764539C204787440 @default.
• W2275764539 hasConceptScore W2275764539C27081682 @default.
• W2275764539 hasConceptScore W2275764539C2776814716 @default.
• W2275764539 hasConceptScore W2275764539C2777907850 @default.
• W2275764539 hasConceptScore W2275764539C2778186239 @default.
• W2275764539 hasConceptScore W2275764539C2778375690 @default.
• W2275764539 hasConceptScore W2275764539C2779034229 @default.
• W2275764539 hasConceptScore W2275764539C2779307984 @default.
• W2275764539 hasConceptScore W2275764539C2908647359 @default.
• W2275764539 hasConceptScore W2275764539C42219234 @default.
• W2275764539 hasConceptScore W2275764539C71924100 @default.
• W2275764539 hasConceptScore W2275764539C99454951 @default.
• W2275764539 hasOpenAccess W2275764539 @default.
• W2275764539 hasRelatedWork W1498758291 @default.
• W2275764539 hasRelatedWork W1711742199 @default.
• W2275764539 hasRelatedWork W1931386098 @default.
• W2275764539 hasRelatedWork W2013331040 @default.
• W2275764539 hasRelatedWork W2014212238 @default.
• W2275764539 hasRelatedWork W2023363152 @default.
• W2275764539 hasRelatedWork W2054181432 @default.
• W2275764539 hasRelatedWork W2095545176 @default.
• W2275764539 hasRelatedWork W2112749639 @default.
• W2275764539 hasRelatedWork W2323575754 @default.
• W2275764539 hasRelatedWork W2411579787 @default.
• W2275764539 hasRelatedWork W2738264200 @default.
• W2275764539 hasRelatedWork W2780953930 @default.
• W2275764539 hasRelatedWork W2905603477 @default.
• W2275764539 hasRelatedWork W2914333425 @default.
• W2275764539 hasRelatedWork W2995607922 @default.
• W2275764539 hasRelatedWork W3183596813 @default.
• W2275764539 hasRelatedWork W3194137475 @default.
• W2275764539 hasRelatedWork W2185600435 @default.
• W2275764539 hasRelatedWork W2339282060 @default.
• W2275764539 hasVolume "80" @default.
• W2275764539 isParatext "false" @default.
• W2275764539 isRetracted "false" @default.
• W2275764539 magId "2275764539" @default.
• W2275764539 workType "article" @default.